Lalo Flores (Century)
As allogeneic cell therapy approaches flourish, Century loads up $160M to scale iPSC platform for CAR-T, CAR-NK
Lalo Flores is confident he’s found the way forward in cell therapy.
The feeling, to be sure, is not exclusive. Thanks to splashy companies like …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
